HeraMED Management

Management Kriterienprüfungen 1/4

We currently do not have sufficient information about the CEO.

Wichtige Informationen

Anoushka Gungadin

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.1yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Anoushka Gungadin

less than a year

Amtszeit

Ms. Anoushka Gungadin is Director of HeraMED Limited from May 10, 2024 and serves as its Managing Director since June 2024. Ms. Gungadin is Chief Executive Officer of HeraMED Limited. Ms. Gungadin was Dire...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Anoushka Gungadin	MD, CEO & Director	less than a year	keine Daten	keine Daten
Paul Friedman	Member of Advisory Board	5.5yrs	keine Daten	keine Daten
David Hinton	Independent Non-Executive Director	6.3yrs	AU$49.98k	0.068% A$ 9.5k
Timothy Chapman	Independent Chairman	less than a year	keine Daten	0.83% A$ 116.1k

3.1yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrener Vorstand: HMD's board of directors are considered experienced (3.1 years average tenure).

HeraMED Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

HeraMED Limited, Annual General Meeting, May 30, 2024

Heramed Limited Announces Board Changes

HeraMED Limited, Annual General Meeting, Feb 23, 2024

HeraMED Limited Announces Emily Slade to Resign as Non-Executive Director

HeraMED Limited Limited Announces Resignation of David Groberman as Chief Executive Officer with Immediate Effect

HeraMED Limited Limited Announces Resignation of David Groberman as Chief Executive Officer with Immediate Effect

Recent updates

HeraMED Limited has completed a Follow-on Equity Offering in the amount of AUD 3.1 million.

First half 2024 earnings released: AU$0.009 loss per share (vs AU$0.014 loss in 1H 2023)

New major risk - Shareholder dilution

New major risk - Shareholder dilution

HeraMED Limited, Annual General Meeting, May 30, 2024

Heramed Limited Announces Board Changes

Full year 2023 earnings released: US$0.017 loss per share (vs US$0.023 loss in FY 2022)

HeraMED Limited, Annual General Meeting, Feb 23, 2024

HeraMED Limited has filed a Follow-on Equity Offering in the amount of AUD 1.285057 million.

HeraMED Limited Announces Emily Slade to Resign as Non-Executive Director

HeraMED Limited Limited Announces Resignation of David Groberman as Chief Executive Officer with Immediate Effect

HeraMED Limited Limited Announces Resignation of David Groberman as Chief Executive Officer with Immediate Effect

New minor risk - Share price stability

New major risk - Market cap size

Less than half of directors are independent

First half 2023 earnings released: US$0.009 loss per share (vs US$0.016 loss in 1H 2022)

HeraMED Limited, Annual General Meeting, Sep 19, 2023

HeraMED Limited has completed a Follow-on Equity Offering in the amount of AUD 2.58 million.

New major risk - Market cap size

Full year 2022 earnings released: EPS: US$0 (vs US$0.033 loss in FY 2021)

HeraMED Limited Announces Appointment of Keith Koby as President, North America

High number of new directors

HeraMED Limited has completed a Follow-on Equity Offering in the amount of AUD 4 million.

HeraMED Limited Appoints Emily Slade as Non-Executive Director

HeraMED Limited Appoints Emily Slade as Non-Executive Director

HeraMED Limited, Annual General Meeting, Oct 12, 2022

HeraMED Limited has completed a Follow-on Equity Offering in the amount of AUD 4 million.

First half 2022 earnings released: US$0.016 loss per share (vs US$0.01 loss in 1H 2021)

HMD Appoints Anoushka Gungadin as Director of Strategic Partnerships Australia and New Zealand

HeraMED Limited Announces Results of Sheba HeraBEAT Clinical Trial

Insufficient new directors

HeraMED Limited Announces Outstanding Results Achieved in Second Jhc Clinical Trial

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

High number of new directors

HeraMED Limited Provides Positive Interim Results US Paid Pilot & 2nd Site Confirmed

Full year 2020 earnings released: US$0.027 loss per share (vs US$0.035 loss in FY 2019)

HeraMED Limited has completed a Follow-on Equity Offering in the amount of AUD 2.332276 million.

HeraMED Limited Announces Sheba Medical Centre, Initiates Pilot to Test Both the HeraBEAT Device and HeraCARE Platform

Hapvida Extends its subscription for HeraCARE SaaS and cloud monitoring services for a further 24 months

HeraMED Limited Signs Letter of Intent with Teleperinatal

HeraMED Limited Announces Partnership with eCare21, Inc & Functional Integration Completed

Heramed Limited Announces Outstanding Clinical Study Results

HeraMED Limited Partnership with Leading Virtual Care Platform eCare21 in US

First half earnings released

HeraMED Limited announced that it expects to receive CAD 0.082999 million in funding

HeraMED Limited has completed a Follow-on Equity Offering in the amount of AUD 2.322419 million.

Geschäftsführer

Amtszeit

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit